Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.481.01%
QQQ
716.261.07%
BTC/USD
78643.162.7554%
DIA
525.440.9%
GLD
401.001.17%
TLT
81.220.55%

Celldex Therapeutics Inc (CLDX) Stock Price, Quote, News & History

CLDXNASDAQ
Trade with Public
Trade with Public
$38.18
0.080.21%
Last update: Sep 11, 10:29 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Celldex Therapeutics (CLDX) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$38.45
Close
-
Volume / Avg.
224.95K / 998.71K
Day Range
$37.67 - $38.59
52 Wk Range
22.10 - 45.14
Market Cap
$3.00B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
38
Short Interest
11.45%
Days to Cover
12.23

Recent Celldex Therapeutics, Inc. News

Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
Avi Kapoor

Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study

Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.
Vandana Singh

Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Avi Kapoor

Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday?

Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government shutdown may soon conclude.
Piero Cingari

Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short

Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom improvement.
Vandana Singh

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-235.57M
Investing Cash Flow (TTM)
-67.13M
Financing Cash Flow (TTM)
327.11M
Free Cash Flow (TTM)
-242.11M
Capital Expenditure (TTM)
-6.54M
Net Change in Cash (TTM)
24.41M

Analyst Trends and Forecast

2
Jun
6
Jul
2
Aug
1
Sep
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$2.28B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
16708.63
PB Ratio (TTM)
4.18
Earnings Yield % (TTM)
-11.43%
Earnings Yield % (FWD)
-11.12%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$9.10

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$47.45M
Debt to Equity
0.01
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$38.45
Close
-
Volume / Avg.
224.95K / 998.71K
Day Range
$37.67 - $38.59
52 Wk Range
22.10 - 45.14
Market Cap
$3.00B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
38
Short Interest
11.45%
Days to Cover
12.23

About

Sector
Health Care
Industry
Biotechnology
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, a...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Celldex Therapeutics (CLDX) stock?

A

You can purchase shares of Celldex Therapeutics (NASDAQ:CLDX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Celldex Therapeutics (CLDX) competitors?

Q

What is the forecast, or price target, for Celldex Therapeutics (CLDX) stock?

A

Celldex Therapeutics has a consensus price target of $55.31.

Q

What is the current price for Celldex Therapeutics (CLDX)?

A

The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $38.18 last updated September 11, 2026 at 10:29 AM EDT.

Q

Does Celldex Therapeutics (CLDX) pay a dividend?

A

There are no upcoming dividends for Celldex Therapeutics.

Q

When is Celldex Therapeutics (NASDAQ:CLDX) reporting earnings?

A

Celldex Therapeutics does not have any upcoming earnings scheduled.

Q

Is Celldex Therapeutics (CLDX) going to split?

A

There is no upcoming split for Celldex Therapeutics.

Q

What sector and industry does Celldex Therapeutics (CLDX) operate in?

A

Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved